UroGen Pharma Ltd
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
URGN$25.32-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Deficit
(unaudited; in thousands, except share amounts)
| Ordinary Shares | ||||||
|---|---|---|---|---|---|---|
| Number of · Additional paid-in · Accumulated · Accumulated other comprehensive | ||||||
| Shares | Amount | capital | Deficit | income (loss) | Total | |
| Balance as of January 1, 2025 | 42,231,746 | $115 | $797,248 | $(806,222) | $56 | $(8,803) |
| Changes During the Three Months Ended March 31, 2025 | ||||||
| Exercise of options into ordinary shares | 288,925 | 1 | 29 | 30 | ||
| Share-based compensation | 3,069 | 3,069 | ||||
| Conversion of pre-funded warrants into ordinary shares | 3,206,271 | 9 | (6) | 3 | ||
| Issuance of ordinary shares, net of issuance costs | 374,843 | 1 | 3,127 | 3,128 | ||
| Other comprehensive loss | (42) | (42) | ||||
| Net loss | (43,843) | (43,843) | ||||
| Balance as of March 31, 2025 | 46,101,785 | $126 | $803,467 | $(850,065) | $14 | $(46,458) |
| Balance as of January 1, 2024 | 32,490,119 | $89 | $614,035 | $(679,348) | 12 | $(65,212) |
| Changes During the Three Months Ended March 31, 2024 | ||||||
| Exercise of options into ordinary shares | 237,100 | 1 | (1) | — | ||
| Share-based compensation | 2,756 | 2,756 | ||||
| Issuance of ordinary shares, net of issuance costs | 3,400,468 | 9 | 54,648 | 54,657 | ||
| Other comprehensive loss | (49) | (49) | ||||
| Net loss | (32,286) | (32,286) | ||||
| Balance as of March 31, 2024 | 36,127,687 | $99 | $671,438 | $(711,634) | $(37) | $(40,134) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.